These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Polyethylene Glycol-conjugated L-asparaginase versus native L-asparaginase in combination with standard agents for children with acute lymphoblastic leukemia in second bone marrow relapse: a Children's Oncology Group Study (POG 8866). Kurtzberg J; Asselin B; Bernstein M; Buchanan GR; Pollock BH; Camitta BM J Pediatr Hematol Oncol; 2011 Dec; 33(8):610-6. PubMed ID: 22042277 [TBL] [Abstract][Full Text] [Related]
5. Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group. Rau RE; Dreyer Z; Choi MR; Liang W; Skowronski R; Allamneni KP; Devidas M; Raetz EA; Adamson PC; Blaney SM; Loh ML; Hunger SP Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29090524 [TBL] [Abstract][Full Text] [Related]
6. Plasma asparaginase activity and asparagine depletion in acute lymphoblastic leukemia patients treated with pegaspargase on Children's Oncology Group AALL07P4 Schore RJ; Devidas M; Bleyer A; Reaman GH; Winick N; Loh ML; Raetz EA; Carroll WL; Hunger SP; Angiolillo AL Leuk Lymphoma; 2019 Jul; 60(7):1740-1748. PubMed ID: 30626253 [TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. Douer D; Yampolsky H; Cohen LJ; Watkins K; Levine AM; Periclou AP; Avramis VI Blood; 2007 Apr; 109(7):2744-50. PubMed ID: 17132721 [TBL] [Abstract][Full Text] [Related]
8. [Efficacy observation of polyethylene glycol conjugated asparaginase for induction treatment of children with newly diagnosed acute lymphoblastic leukemia]. Liu F; Wan Y; Chang L; Guo Y; Yang W; Wang S; Chen X; Liu T; Ruan M; Zhang L; Liu X; Zou Y; Chen Y; Zhu X Zhonghua Er Ke Za Zhi; 2014 Mar; 52(3):215-7. PubMed ID: 24824393 [TBL] [Abstract][Full Text] [Related]
9. Serum asparaginase activities and asparagine concentrations in the cerebrospinal fluid after a single infusion of 2,500 IU/m(2) PEG asparaginase in children with ALL treated according to protocol COALL-06-97. Vieira Pinheiro JP; Wenner K; Escherich G; Lanvers-Kaminsky C; Würthwein G; Janka-Schaub G; Boos J Pediatr Blood Cancer; 2006 Jan; 46(1):18-25. PubMed ID: 15929133 [TBL] [Abstract][Full Text] [Related]
10. Asparagine concentration in plasma after 2,500 IU/m(2) PEG-asparaginase i.v. in children with acute lymphoblastic leukemia. Wenner KA; Vieira Pinheiro JP; Escherich G; Wessalowski R; Jorch N; Wolff J; Stehn M; Kohlschütter A; Boos J; Janka-Schaub GE Klin Padiatr; 2005; 217(6):321-6. PubMed ID: 16307417 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics-based integration of multiple doses of intravenous pegaspargase in a pediatric regimen for adults with newly diagnosed acute lymphoblastic leukemia. Douer D; Aldoss I; Lunning MA; Burke PW; Ramezani L; Mark L; Vrona J; Park JH; Tallman MS; Avramis VI; Pullarkat V; Mohrbacher AM J Clin Oncol; 2014 Mar; 32(9):905-11. PubMed ID: 24516026 [TBL] [Abstract][Full Text] [Related]
12. Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia. Hawkins DS; Park JR; Thomson BG; Felgenhauer JL; Holcenberg JS; Panosyan EH; Avramis VI Clin Cancer Res; 2004 Aug; 10(16):5335-41. PubMed ID: 15328169 [TBL] [Abstract][Full Text] [Related]
14. FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL). Dinndorf PA; Gootenberg J; Cohen MH; Keegan P; Pazdur R Oncologist; 2007 Aug; 12(8):991-8. PubMed ID: 17766659 [TBL] [Abstract][Full Text] [Related]
15. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. Avramis VI; Sencer S; Periclou AP; Sather H; Bostrom BC; Cohen LJ; Ettinger AG; Ettinger LJ; Franklin J; Gaynon PS; Hilden JM; Lange B; Majlessipour F; Mathew P; Needle M; Neglia J; Reaman G; Holcenberg JS; Stork L Blood; 2002 Mar; 99(6):1986-94. PubMed ID: 11877270 [TBL] [Abstract][Full Text] [Related]
16. Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia. Silverman LB; Supko JG; Stevenson KE; Woodward C; Vrooman LM; Neuberg DS; Asselin BL; Athale UH; Clavell L; Cole PD; Kelly KM; Laverdière C; Michon B; Schorin M; Schwartz CL; O'Brien JE; Cohen HJ; Sallan SE Blood; 2010 Feb; 115(7):1351-3. PubMed ID: 20007809 [TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamics of cerebrospinal fluid asparagine after asparaginase. Panetta JC; Liu Y; Bottiglieri T; Arning E; Cheng C; Karol SE; Yang JJ; Zhou Y; Inaba H; Pui CH; Jeha S; Relling MV Cancer Chemother Pharmacol; 2021 Oct; 88(4):655-664. PubMed ID: 34170389 [TBL] [Abstract][Full Text] [Related]